BlogBlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease Posted Date : Jan 11, 2021 BlueRock Therapeutics shared a news release on January 7, 2020 announcing the funding of a two-year trial using adult donor stem cells. Parkinson Canada’s view: This news is a “[s]ignificant development in North America as the US FDA approves it’s first trial to study the use of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease. The system uses adult donor cells as starting material and reprograms them into dopaminergic neurons that are transplanted into the Parkinson’s region of the brain. In New York, the two-year phase I clinical trial will enroll 10 patients and focus on examining the safety and tolerability of the transplant.” Read the full article in context. Share this post: Your Story Matters: Inspire and Connect Inspire hope and connect with others by sharing your Parkinson’s journey. Your voice can make a difference. Share your story Discover more like this Apr 2, 2024 Living well with Parkinson’s is possible - Parkinson Canada marks Parkinson’s Awareness Month in April Mar 27, 2024 Canadian Open Parkinson Network opens new Halifax site Mar 4, 2024 VYALEV (foslevodopa/foscarbidopa solution) is now available in Canada